Global Blood Therapeutics' Voxelotor On Track For 2020 Sickle Cell Shakeup
The company's NDA for voxelotor was accepted by the US FDA for priority review with action expected in February, setting up a showdown with Novartis.
The company's NDA for voxelotor was accepted by the US FDA for priority review with action expected in February, setting up a showdown with Novartis.